Roche and GlaxoSmithKline (GSK) have announced their new CEO designates, who are both in their early forties. Andrew Witty, of GSK, is 43 years old, while Severin Schwan, of Roche, is a mere 40 years old. Have these pharmaceutical giants made the right decision in investing in these relatively young executives? And what makes a good CEO? Experience is valuable in decision making, so are leadership qualities and good communication skills - as well as a certain naivety, and a willingness to take risks. CEOs also need to be able to draw on the experience of those around them, to surround themselves with talent and with those that share their strong vision. They also have to have energy and mental agility, factors that are normally - but not exclusively - attributable to youth. I believe that Roche and GSK have made the right decision from an age perspective. The remaining qualities of these two CEO designates will be tested as they lead their respective companies over the next five years, and we will be watching with interest.